![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor
|
|
|
EASL International Liver Congress, June 23-26, 2021 JNJ-3989
N Mani1*, AG Cole1, SG Kultgen1, A Ardzinski1, T Chiu1, A Cuconati1, BD Dorsey1, K Fan1, I Graves1, J-T Guo2, TO Harasym1, Z Hu2,
R Kowalski1, J Kunta1, AM Lam1, ACH Lee1, B Liu1, E Mesaros1,
R Rijnbrand1, HMM Steuer1, K Stever1, S Tang1, X Teng1, EP Thi1, and MJ Sofia1
1Arbutus Biopharma; 2Blumberg Institute
![0628211](../images/082521/062821-1/0628211.gif)
![0628212](../images/082521/062821-1/0628212.gif)
![0628213](../images/082521/062821-1/0628213.gif)
![0628214](../images/082521/062821-1/0628214.gif)
![0628215](../images/082521/062821-1/0628215.gif)
![0628216](../images/082521/062821-1/0628216.gif)
![0628217](../images/082521/062821-1/0628217.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|